pisco_log
banner

Value Creation in an Expansion-Phase Bio-Manufacturing Firm: Evidence from EVA at Huaheng Bio (20202024)

Rui Tang

Abstract


This paper evaluates value creation at Huaheng Biotech during its expansion phase using Economic Value Added (EVA) based on
publicly disclosed annual reports for 20202024. EVA is measured as after-tax operating profit net of a capital charge, with the cost of capital
estimated through a consistent WACC procedure. The results show a clear turning point: EVA remains positive through 2023 but turns negative in 2024, indicating that operating profit realization failed to cover the opportunity cost of the enlarged invested-capital base. Decomposition suggests the reversal is jointly driven by a sharp decline in profit realization and a higher capital charge associated with rapid capitalbase growth. The findings imply that expansion can compress value creation when capital-to-profit conversion lags, highlighting the need for
disciplined capital allocation and stronger liquidity resilience during the conversion period.

Keywords


Economic value added (EVA); Value creation; Capital charge; Expansion phase; Capital allocation

Full Text:

PDF

Included Database


References


[1] Huang J, Mei Z, Li Z. Business and financial information integration and voluntary management earnings forecasts[J]. China Journal of

Accounting Research, 2020, 13(3): 291-307.

[2] Gao J. Research on financial informatization construction of business and finance integration[J]. International Journal of Science and

Research (IJSR), 2022, 11(7): 354-358.

[3] Chen Y, Jin Z, Qin B. Economic Value Added in performance measurement: A simulation approach and empirical evidence[J]. Accounting & Finance, 2023, 63(1): 109-140.

[4] Tripathi P M, Chotia V, Solanki U, et al. Economic value added research: Mapping thematic structure and research trends[J]. Risks,

2022, 11(1): 9.




DOI: http://dx.doi.org/10.70711/memf.v3i3.8852

Refbacks

  • There are currently no refbacks.